
When it comes to men’s health, few topics create as much debate and confusion as prostate cancer screening.
The prostate-specific antigen (PSA) test has long been the primary tool used to screen for prostate cancer, but the approach has evolved. Advances in prostate imaging, biomarker testing, and other methods of evaluation now provide men and their doctors with more information to assess prostate cancer risk and determine whether a biopsy may be needed.
Here’s what men should know about today’s screening and evaluation options.
Why is prostate cancer screening important?
About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, making it the second-leading cause of cancer death among American men.1 Because early-stage prostate cancer often causes no symptoms, screening plays a critical role in early detection. When prostate cancer is diagnosed while still confined to the prostate, the five-year relative survival rate is more than 99%, compared with 38% when the cancer has spread to distant parts of the body.2
How prostate cancer screening has changed
Given the importance of early detection, screening might seem like an obvious choice. But it hasn’t always been that simple.
When PSA testing became widely used, it helped detect prostate cancer earlier. However, the test has limitations. An elevated PSA doesn’t necessarily mean a man has cancer, and the test can’t determine how aggressive a cancer is or whether it needs treatment. This sometimes led to unnecessary biopsies and treatment for slow-growing cancers that may never have caused harm.3-5
In response, concerns about overdiagnosis and overtreatment led to the 2012 U.S. Preventive Services Task Force recommendation against routine screening.6 Screening rates subsequently declined, raising concerns that some men, particularly those at increased risk of aggressive disease, might miss opportunities for early detection.7
Since then, PSA screening has evolved toward a more personalized approach, with decisions about screening based on a man’s age, family history, and individual risk factors. When further evaluation is needed, additional tools help determine whether a biopsy is warranted and, if cancer is found, whether treatment is necessary.
When should you consider screening?
Screening recommendations depend on age and individual risk. The 2026 NCCN guidelines recommend considering screening at different ages based on risk:8
- Increased risk (ages 40–75): Black and African American men, those with inherited genetic mutations such as BRCA1 or BRCA2, and those with a concerning family history of certain cancers, such as prostate cancer, should consider screening beginning at age 40.
- Average risk (ages 45–75): Screening discussions and a baseline PSA test should generally begin around age 45.
- Over age 75: Screening should be individualized and generally reserved for men with a life expectancy of at least 10 years, while others may consider stopping.
How often should you be screened?
How often you are screened will depend on a few factors, including your PSA level, your personal risk, and your health. Your doctor can help you interpret your PSA levels and establish a screening schedule that’s right for you.
For more detailed screening recommendations, visit the National Comprehensive Network (NCCN).
The PSA test: still the foundation of prostate cancer screening
PSA is a protein produced by cells within the prostate gland. Both normal and cancerous prostate cells produce PSA, and elevated levels could signal the presence of prostate cancer.
However, PSA levels can also rise for other reasons, including an enlarged prostate, inflammation or infection, recent ejaculation, or prostate injury.
If PSA levels are elevated, doctors may recommend repeating the test before proceeding with additional evaluation. This helps determine whether the increase is temporary or persistent.
What happens if your PSA remains elevated?
Historically, an elevated PSA often led to prostate biopsy to determine whether cancer was present. Although a biopsy is generally needed to confirm a prostate cancer diagnosis, it is invasive and can cause complications such as infection, bleeding, and discomfort. Additionally, a biopsy can sometimes miss cancer if the tissue samples do not include the affected area.
Today, doctors use a more thorough evaluation process when PSA levels remain elevated or continue to rise. Evaluation tools can help assess the likelihood of significant prostate cancer and determine whether a biopsy or continued monitoring is appropriate.
Tools used to evaluate prostate cancer risk
No single test provides all the answers. Doctors may use several tools together to better understand a patient’s risk and determine whether further testing is needed.
Digital Rectal Exam (DRE)
A DRE is a quick physical exam in which a doctor feels the back of the prostate through the rectal wall to check for unusual lumps or hard areas. Because only part of the prostate can be felt, some cancers may go undetected. However, a DRE can still provide useful information, particularly in men with elevated PSA levels, and therefore it remains as an optional tool in the evaluation process.9
Multiparametric Prostate MRI (mpMRI)
One of the most important evaluation tools is mpMRI, which provides detailed images of the prostate to help identify suspicious areas that may need further investigation. These images can also help doctors target suspicious areas during a biopsy.
The benefits of using mpMRI before biopsy have been demonstrated in several clinical studies. For example, the PROMIS trial (2017) found that an MRI-first approach could allow approximately 27% of men to avoid an initial prostate biopsy while improving the detection of clinically significant prostate cancers that may benefit from treatment.10
PSA density
PSA density compares a man’s PSA level with the size of his prostate. Because larger prostates naturally produce more PSA, this measurement can help doctors determine whether an elevated PSA level may be related to prostate enlargement or warrants further investigation. When considered alongside MRI findings, it can help guide decisions about biopsy.11
Blood and urine biomarker tests
Doctors may also use specialized blood and urine tests, known as biomarker tests, to help assess prostate cancer risk. These tests look for proteins or genetic material associated with prostate cancer and can help estimate the likelihood of finding cancer that may require treatment.
Examples include blood tests such as the Prostate Health Index (PHI) and 4Kscore®, as well as urine tests that look for genetic markers associated with prostate cancer.
Research suggests that these tests can help some patients avoid unnecessary biopsies, although they are not definitive and may miss some cancers.12
Risk calculators
Risk calculators are easy-to-use and fast online tools that help doctors and patients estimate a man’s likelihood of having prostate cancer. Depending on the calculator, they may consider several clinical factors, including age, PSA level, family history, ancestry, DRE findings, and any previous biopsy result. Commonly used calculators include Sunnybrook, ERSPC, and PCPT.
Taking control of your health
If there’s one thing to take away from this, it’s that prostate cancer screening should reflect your individual risk and health. The best place to start is a conversation with your doctor about when you should be screened, what your PSA results mean, and what options are available if something doesn’t look right.
And if you’re diagnosed with prostate cancer, treatment isn’t always the immediate next step. For some men, active surveillance may be a good option. Deciding between active surveillance and treatment are also personal decisions, and newer tools like genomic testing can provide additional information to help guide that choice. Learn more about how genomic testing can help guide these decisions.
Ultimately, the goal is to understand your options and feel confident in the decisions you make about your health.
Medical Disclaimer: This article is for educational purposes only and does not replace individualized medical advice, diagnosis, or treatment.
References
- https://www.cancer.org/cancer/types/prostate-cancer/key-statistics.html
- https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/survival-rates.html
- https://www.nejm.org/doi/full/10.1056/NEJMoa0810084
- https://www.nejm.org/doi/full/10.1056/NEJMoa0810696
- https://www.nejm.org/doi/full/10.1056/NEJMoa2214122
- https://pubmed.ncbi.nlm.nih.gov/22801674/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11682208/
- https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf
- https://www.auajournals.org/doi/abs/10.1016/j.juro.2017.10.021
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32401-1/fulltext
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2816957
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11321723/
Leave a Reply